Investor Relations

Investor Relations

Corporate Profile

KDNY

Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.

Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

IR Contact

Noopur Liffick

Vice President
Investor Relations & Corporate Communications
investors@chinooktx.com
510.809.2465